Related references
Note: Only part of the references are listed.Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Katherine E. Hutchinson et al.
CLINICAL CANCER RESEARCH (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis
Sandhya Manohar et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters
Chenxi Yuan et al.
SCIENTIFIC REPORTS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
J. H. Park et al.
ANNALS OF ONCOLOGY (2019)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Nadia Howlader et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Mirjana Efremova et al.
NATURE COMMUNICATIONS (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
Thomas Karn et al.
JAMA ONCOLOGY (2017)
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
Ahrong Kim et al.
SCIENTIFIC REPORTS (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Ashley Cimino-Mathews et al.
HUMAN PATHOLOGY (2016)
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
George Plitas et al.
IMMUNITY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness
H. Gilbert Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Luc G. T. Morris et al.
ONCOTARGET (2016)
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
Tingting Jiang et al.
PLOS MEDICINE (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Why have breast cancer mortality rates declined?
Steven A. Narod et al.
JOURNAL OF CANCER POLICY (2015)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Leukocyte composition of human breast cancer
Brian Ruffell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
